Allergy Therapeutics plc (AIM:AGY)

Market Cap	657.13M
Revenue (ttm)	55.66M
Net Income (ttm)	-35.65M
Shares Out	6.14B
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	249,302
Average Volume	522,609
Open	10.00
Previous Close	10.50
Day's Range	9.83 - 10.70
52-Week Range	5.00 - 10.90
Beta	0.80
RSI	75.82
Earnings Date	Dec 29, 2025

About Allergy Therapeutics

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders. The company sells injectable and sublingual allergen-specific immunotherapies; and offers treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to ad...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 612
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: AGY

Financial Performance

In 2024, Allergy Therapeutics's revenue was 55.20 million, a decrease of -7.36% compared to the previous year's 59.59 million. Losses were -40.22 million, -6.63% less than in 2023.